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Introduction: Alzheimer’s disease (AD) is a neurodegenerative condition that is prevalent in today’s 
society and is on the rise. A disturbance of the circadian rhythm is an early symptom and is associated 
with disrupted sleep/wake cycles. CLOCK genes, important in regulating the circadian rhythm, have 
been hypothesised to regulate important factors in neurodegeneration. These CLOCK genes control 
circadian timekeeping by regulating their own expression over 24hours via a series of interacting 
positive & negative feedback loops; with BMAL1 being a key gene that drives the circadian cycle. 
Sleep disturbances are observed in AD and the reasons for this may be multifactorial and involve 
beta-amyloid (Aβ), light exposure and sleep disordered breathing (SDB), which are all related to the 
circadian cycle. Circadian dysfunction is hypothesised to contribute to AD pathogenesis and previous 
studies show a link between the circadian clock, AD neuropathology, sleep regulation and cognition; 
particularly fluid intelligence, processing speed, memory and vocabulary. However, it is unclear if 
circadian dysfunction within AD is causal or consequential to the development of neuropathology.  
Aim: To investigate if BMAL1 methylation is epigenetically regulated in brains in relation to AD 
neuropathology, longitudinal changes in cognition, sleep quality and depressive symptoms. This 
study is designed to assess the hypothesis that BMAL1 methylation will directly affect 
neuropathology, cognition, sleep quality and depression. 
Methods: Prefrontal cortex (n=96) samples were acquired from Manchester Brain Bank. DNA 
methylation at six individual CpG sites on BMAL1 was determined using bisulphite pyrosequencing 
that was statistically tested for associations with AD neuropathology, longitudinal changes in 
cognition, sleep quality and depressive symptoms (BDI score).  
Results: Methylation across all the CpGs strongly correlated with each other. We found increased 
CpG2 methylation with higher Braak (F (1, 92)=6.1, p=0.015) stages. No significance was found 
between longitudinal fluid intelligence, processing speed and memory tests, but methylation at CpG1 
(r=0.20, p=0.05) and CpG4 (r=0.20, p=0.05) positively correlated with vocabulary. When testing for 
age-adjusted cross-sectional data, CpG2 positively correlated with cross-sectional fluid intelligence 
(r=0.20 p=0.05) and vocabulary (r=0.22 p=0.03). Though longitudinal analysis revealed no 
significance between sleep duration, midsleep and efficiency for any of the CpG sites, CpG3 (B=0.03, 
95%CI=0.00/0.06, p=0.03) and CpG5 (B=0.04, 95%CI=0.01,0.07, p=0.01) significantly correlated with 
night wake. CpG4 correlated with depressive symptoms (B=-0.27, 95%CI=0.49/-0.05, p=0.02).  
Discussion: The results of this study indicate that DNA methylation of BMAL1 is positively associated 
with AD neuropathology, longitudinal changes in cognition, sleep quality and depression; suggesting 
that the circadian cycle plays a linking role in regulating these key factors in the development of AD. 
Further research is needed to understand the dynamics of this relationship. 





1.1 Epidemiology of Dementia/Alzheimer’s Disease 
Dementia is the umbrella term used to describe a set of symptoms that affect memory, 
behaviour, thinking and emotion and currently in the UK, 1 in 14 people aged over 65 
have dementia (Prince et al., 2014). There are over 100 different forms of dementia, 
with Alzheimer’s Disease (AD) being the most prevalent and accounting for 60-80% of 
all cases of dementia (Alzheimer’s, 2016). AD is a neurodegenerative condition which is 
clinically characterised by a gradual, insidious onset of memory loss which then expands 
into multi-domain cognitive impairment (Musiek, 2017). Pathological hallmarks of AD 
are beta-amyloid plaques (Aβ) and neurofibrillary tangles (NFT), formed from the 
aggregation of misfolded tau protein. Aβ plaques occur when the two major enzymes 
neprilysin (NEP) and insulin degrading enzyme (IDE) decrease with normal ageing and in 
disease-affected regions (Caccamo et al., 2005). Additionally, NEP has been shown to 
decrease in cerebral spinal fluid (CSF) in early AD (Maruyama et al., 2005).  
Amongst the symptoms listed above, disturbances to sleep and day-night rhythms are 
also very common. Sleep problems in AD patients are observed with over 60% of 
individuals with mild cognitive impairment (MCI) or dementia experiencing sleep 
disturbances (Guarnieri et al., 2012), as well as circadian rhythm disruption and 
misalignment (Phan & Malkani, 2019). Sleep and circadian rhythms are very closely 
correlated, but they have separate neuroanatomical and molecular substrates. 
Circadian dysfunction may contribute to AD pathogenesis and this will be discussed 
further in this study. 
 
1.2 The Circadian Clock 
Circadian rhythm, also known as sleep/wake cycle, is a biological system that acts as a 
24-hour internal clock and regulates feelings of sleepiness and wakefulness throughout 
this time.  Circadian rhythms exist in the majority of living organisms and are responsible 
for many behavioural and biochemical processes. The primary aim of the circadian 
system is to synchronise internal functions with the external environment; with 
particular focus on the light-dark cycle (Musiek, 2017). The circadian system that 
generates circadian rhythms in mammals, which consists of a central clock, is located in 
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the suprachiasmatic nucleus (SCN) of the hypothalamus with peripheral clocks in 
majority of other cells (Tomita & Onishi, 2018). The SCN sends signals to other brain 
areas, including sleep-wake centres, the pineal gland to regulate melatonin and to 
regions that regulate autonomic function and hormone secretion (Colwell, 2011).  
 
The circadian clock consists of a transcription-translation feedback loop, which is 
regulated by clock genes. These genes include, brain and muscle Aryl Hydrocarbon 
Receptor Nuclear Translator-Like 1 (ARNTL, also known as BMAL1), clock circadian 
regulator (CLOCK), cryptochrome (CRY1 & CRY2) and period circadian clock (PER1, PER2 
& PER3) and these are the core circadian genes in peripheral or central tissues (Kelsbeek 
et al., 2014). It is the interlocked transcriptional and post-translational negative 
feedback loops which are responsible for both the generation and preservation of 
circadian rhythms. BMAL1 and CLOCK are transcription factors that act as positive 
regulators of circadian gene expression, which in turn activates the expression of the 
negative regulators CRY1 and CRY2, PER1, PER2 and PER3 and REV-ERB (Nr1d1 & Nr1d2) 
(Kelsbeek et al., 2014). Nr1d1 & Nr1d2, which is a nuclear receptor that regulates lipid 
metabolism and adipogenesis, directly and indirectly represses BMAL1/CLOCK-
mediated transcription. Additionally, Retinoic Acid Receptor-related Orphan Receptors 
(RORs) which are made up of RORα, RORβ and RORγ are all involved in the functioning 
of circadian rhythm and RORα is a positive regulator of BMAL1. A new transcriptional 
cycle starts through the proteolytic degradation of PER and CRY, when the 
CLOCK:BMAL1 complex becomes de-repressed (Figure 1). 
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Figure 1: Molecular core clock mechanism. CLOCK:BMAL1, PER1-3 & CRY1&2 form the core loop 
with CLOCK:BMAL1 heterodimers driving PER1-2 & CRY1&2 transcription. PERs & CRYs 
heterodimers move to the nucleus which inhibits CLOCK:BMAL1 activity; thus the transcriptional 
activity of CLOCK:BMAL1 drops. This reduces the transcription of PER and CRY genes, which in turn 
activates CLOCK:BMAL1. REV-ERB and RORs enhance the efficiency of the core loop. Adapted from 
Spek et al., (2012). 
 
The circadian system has a large influence on multiple aspects of physiology with the 
rhythmic clock gene expression being characterised in peripheral tissues, such as skin 
(Bjarnason et al., 2001), bone marrow (Kusanagi et al., 2008) white blood cells (Archer 
et al., 2008) and the heart (Leibetseder et al., 2009). However, due to the nature of the 
human brain and only being able to examine these oscillators in post-mortem, it is very 
difficult to look at the circadian rhythm in the brain. As the circadian system is 
implemented in many physiology processes, a severe disruption in this regulation is 
associated with the heightened and worsening of many disease states; including 
neurodegeneration in mice, (Musiek et al., 2013), coronary heart disease (Vetter et al, 
2016) and breast cancer (Davis et al., 2001) in humans, and other metabolic problems 
(Cribbet et al, 2016).  
 
Circadian dysfunction has been previously linked to neurodegeneration in AD, with 
different studies hypothesising it as both a consequence of and a potential contributor 
to the pathogenesis of AD (Hastings & Goedert, 2013; Musiek & Holtzman, 2016). This 
issue is the subject of this study. 
  
1.3 Neuropathology of Circadian Dysfunction in Alzheimer’s Disease 
The brain changes associated with AD are thought to begin 20 years or more before 
clinical symptoms appear (Reiman et al., 2012). Circadian disruption in AD patients is 
partly mediated by changes and degeneration of the SCN. The SCN experiences neuronal 
loss during normal aging, however AD patients exhibit significantly higher neuronal loss 
(Stopa et al., 1999). Circadian rhythm is portrayed in which levels of a particular measure 
(BMAL1 methylation), varies depending on the time. The difference between peak and 
trough values is called the amplitude of the rhythm. The phase of the rhythm is the 
timing of the referred to point in the cycle, for example the peak, relative to the fixed 
event, for example entering the night phase. The period of the rhythm is the time 
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interval between phase referred to points, for example between the two peaks 
(Vitaterna et al., 2000). Studies show a correlation between circadian rhythm amplitude 
of motor activity and SCN neuronal loss when comparing AD and cognitively healthy 
subjects (Wang et al, 2015). Wang et al., (2015) studied the loss of vasoactive intestinal 
peptide (VIP) and found it to be correlated with a decline in the amplitude of behavioural 
circadian rhythms. This is due to VIP and neuronal expression of Arginine Vasopressin 
(AVP) playing key roles in SCN synchronization and circadian rhythm output (Aton et al., 
2005; Meida et al., 2016). Additionally, several studies show blunted circadian 
oscillations in melatonin secretion in AD patients (Mishima et al., 1999; Skene & Swaab, 
2003). This is down to the pineal gland receiving output from the SCN which generates 
circadian oscillations in melatonin secretion (Wu et al., 2006). Furthermore, significant 
changes in methylation have been reported in AD patients (De Jager et al., 2014), 
particularly in the frontal cortex (Lim et al., 2014). However, the pathways that cause 
this still remain unexplored.  
A hallmark of AD are deficits in executive functioning affecting skills such as working 
memory, fluid intelligence and processing speed and the frontal cortex has been widely 
associated with these functions. The frontal cortex is also highly sensitive to sleep 
changes (Wu et al., 2006).  A PET study found that changes in this region, including the 
superior frontal gyrus, were present in patients with MCI that progressed to Alzheimer's 
disease (AD) compared to those that did not (Valdés et al., 2018). Accumulating 
evidence, especially in animal models, suggests that circadian clock dysfunction could 
promote neurodegeneration and contribute to AD pathogenesis. Studies in transgenic 
AD mice models have found that chronic sleep restriction and deprivation exacerbates 
AD pathology in brains, including increased amyloid-β (Aβ) and phosphorylated tau 
(Rothman et al., 2013; Qui et al., 2016; Di Meco et al., 2014). 
 
To summarise, it is hypothesised that both the degeneration of the SCN and 
dysregulation of pineal melatonin secretion cause clock gene rhythms to be altered and 
in turn, disrupt the circadian clock. Not much is known about DNA methylation in AD 
brains and circadian dysfunction, however it is a possibility that DNA methylation 
contributes to the dysregulation of the circadian cycle.  
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1.4 Neuropathology and Braak Score 
Braak & Braak, (1991) found that neurofibrillary tangles and neuropil threads exhibit a 
characteristic distribution pattern permitting the differentiation of six stages. Stages 1-
2 were characterised by an either mild or severe change to the transentorhinal layer 
Pre-α. Stages 3-4 (limbic stages) were characterised by a conspicuous affection of layer 
Pre-α in both transentorhinal region and proper entorhinal cortex. Stages 5-6 
(isocortical stages) refers to the destruction of the majority of the isocortical association 
areas. 
 
1.5 Sleep and Alzheimer’s Disease 
Disturbances in sleep and disruptions in circadian rhythms are common in AD patients 
and studies report that up to 45% of patients have sleep disturbances (Moran et al., 
2005). AD patients exhibit disturbances in sleep-wake cycles and rest-activity 
dysfunction which is primarily due to a higher level of wakefulness at night; caused by 
an increase in nocturnal awakenings (Hatfield et al., 2004). Consequentially, this further 
leads to an increase in sleep during the day, causing a disruption of day-night variation. 
Therefore, though the main cause of sleep disturbances in AD is hypothesised to be 
multi-factorial without a main effect, it appears sleep has some role.  
 
There are several factors that could influence sleep disorders in AD. For example, lack 
of daylight exposure, which is common in AD patients, can directly affect circadian 
rhythms (Figueiro, 2017). AD patients have a higher risk for showing obstructive sleep 
apnoea (OSA) with an estimated ~70-80% of AD patients presenting with this (Wennberg 
et al., 2017). Sleep disordered breathing (SDB) which is also common in AD affects 
circadian rhythm (Hermann & Bassetti, 2016) and is associated with increases as 
dementia symptoms worsen. For example, SDB was found to be associated with an 
increased risk of developing cognitive impairment when compared against those 
without SDB (Yaffe et al., 2011). As many of these all are present in AD, it could pose the 
question whether these factors, particularly SDB, could contribute to the cognitive 
impairment that accompanies AD. 
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Additionally, it has been suggested, that one cause of disrupted sleep in AD patients, is 
Aβ accumulation. Studies in transgenic mice demonstrate that the amyloid precursor 
protein (APP) which is processed into Aβ deposition in the brain, causes an increase in 
wakefulness and an overall decrease in sleep. This initiates when the amyloid plaques 
began to accumulate in the cortex and hippocampus (~ 6 months of age), and then a 
significant disruption in sleep pattern was observed when the plaques became more 
widespread (~9 months of age) (Roh et al., 2012). Other Aβ studies in mice show an 
abnormality in altered nocturnal activity levels (Sterniczuk et al., 2010), phase delay 
(Duncan et al., 2012) and decreased non rapid-eye movement (REM) sleep (Jyoti et al., 
2010). Hence, it could be hypothesised that these Aβ accumulations cause sleep 
disturbances in mice and could mimic potential aspects of AD in humans. 
 
Another aspect to Aβ dynamics is the alterations and degradation of BMAL1 and PER2. 
Song et al., (2015) found the changes in circadian rhythm caused by Aβ, correlated with 
the accelerated degradation of BMAL1 in mice that express 5 familial AD mutations. 
Furthermore, the degradation of BMAL1, induced circadian rhythm disruption by 
dysregulating PER2 expression. This would suggest that BMAL1 is critically correlated 
with circadian rhythm and AD and thus is the focus of this study. 
 
1.6 BMAL1 Gene Methylation 
Epigenetic regulation has been linked to the pathogenesis of neurodegenerative 
diseases due to the vital role it plays in regulating genes involved in neuronal function 
(Cholewa-Waclaw et al., 2016; Aarons et al., 2019). Epigenetics refers to potentially 
heritable and non-heritable changes in gene expression caused by environmental 
factors, independent of the DNA base sequences (Murgatroyd & Spengler, 2011).  
 
DNA methylation is the most common epigenetic modification and consists of a covalent 
chemical modification of a base that plays a crucial role in many biological processes 
where alteration has been linked in AD pathology (Irier & Jin, 2012). In mammals, DNA 
methylation occurs almost entirely in the symmetric CG context and is estimated to 
occur at ~70-80% of CG dinucleotides throughout the genome (Ehrlich et al., 1982). The 
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remaining non-CG methylation is found in embryonic stem cells, and unmethylated CG 
dinucleotides which are mostly found near gene promoters in dense clusters; called CpG 
islands (Suzuki & Bird, 2008). CpG islands are short interspersed DNA sequences that 
deviate significantly from the typical genomic pattern by being CpG-rich, GC-rich and 
generally nonmethylated (Deaton & Bird, 2011). CpG islands are DNA methylations 
regions situated in promoters which are known to regulate gene expression by 
transcriptional silencing of the corresponding gene (Lim et al., 2019). CpG methylation 
is tightly regulated and any changes in methylation profiles are associated with diseases. 
This indicates a close relationship among DNA methylation sites, the mechanism of 
methylation and biological functions (Tomita & Onishi, 2018). 24-hour methylation 
rhythms have recently been described in the frontal cortex and these cycles appear to 
be correlated with age and dementia (Lim et al, 2013). Studies suggest that global 
methylation levels are higher in the prefrontal cortex in individuals with AD, when 
compared with control (Coppieters et al., 2014; Rao et al., 2012).  
 
 
The BMAL1 gene itself is a core gene in the circadian rhythm and has been linked to 
haematological malignancies. The CpG islands in the promoter of BMAL1 are 
hypermethylated, which silences the expression in haematological malignancies, such 
as acute lymphocytic and myeloid leukaemia’s (Taniguchi et al., 2009). Taniguchi et al., 
(2009), found epigenetic inactivation of BMAL1 prevented the activation of CLOCK 
protein to targeted areas; enhancing the disrupted circadian rhythm in malignant cells. 
These findings suggest the epigenetic inactivation of BMAL1 contributes to disruption 
of the cellular circadian clock.  
 
Additionally, altered circadian transcription of BMAL1 in the mid frontal cortex and 
fibroblasts of humans, have been associated with abnormal BMAL1 methylation in AD 
when compared with controls (Cronin et al., 2017). Cronin et al., (2017) found that in 
post mortem mid frontal cortex samples, oscillatory patterns had significant differences 
in methylation at peak times when comparing between early and late AD cases; 
potentially representing underlying changes to the phase and amplitude to circadian 
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rhythm. This difference across the disease states suggest that this may be a molecule 
marker of progression. 
 
The above studies suggest that the epigenetic regulation of BMAL1 plays an important 
role in AD via deregulation of circadian rhythms, however the link between the two has 
yet to be fully explored. 
 
1.7 Depression and Alzheimer’s Disease 
Depression occurs in up to 20% of patients with AD (Valkanova et al., 2017) but the 
relationship is still not fully understood. It has been hypothesised that depression is a 
risk factor for AD (Diniz et al., 2013; Gao et al., 2013), however the underlying molecular 
mechanisms have not been fully explored. Ganguli (2009), came to the conclusion that 
there was no single cause but more a series of factors that interact with each other in 
various ways at different points during the course of life. However, depression has been 
found to damage neurons and one way it does this is amyloid deposition and 
neurofibrillary formation (Rapp et al., 2006). In particular, a lifetime history of 
depression is linked to an increase in Aβ plaques. Disruptions in circadian rhythms has 
been associated with depression (Abarca et al., 2002) and individuals with an arrhythmic 
biological clock have been associated with a higher risk of developing depression 
(McClung, 2007).  
 
Additionally, BMAL1 was found to be hypermethylation in patients with bipolar disorder 
when compared against healthy control (Bengesser et al., 2016). It was also 
hypothesised that a decrease in BMAL1 methylation may lead to an increase in BMAL1 
gene expression and increase in the dopamine (DA) breakdown seen in depression. 
Furthermore, DA levels in the brain are suspected to influence mood in human & mice 
(Andretic & Hirsh, 2000; Nestler & Carlezon, 2006; Roybal et al., 2007) and DA levels 
drop with aging. This supports the hypothesis that altered epigenetic regulation of 
BMAL1 may provide a mechanistic basis for circadian rhythms and mood swings and 
depression (Hampp et al., 2008). 
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The relationship between BMAL1 and neuropathology (Braak score), cognition, sleep 
and depression will be explored in this study using DNA methylation. It is hypothesised 
that BMAL1 could be regulated differently in the brain of AD patients and this study will 
be looking at this by using AD brains and controls and observing any correlations 




2.0 Aims & Objectives 
 
2.1 Aims 
The experimental hypotheses are to determine epigenetic DNA methylation levels of 





The molecular mechanisms surrounding the important clock gene BMAL1 and its role in 
neuropathology, cognition, sleep and depression in regard to AD, still remains relatively 
unknown. A collection of prefrontal cortex brains (n=96) were assessed using their 
predetermined Braak score (determined by the brain bank), assessed longitudinally for 
both change in cognition, and using past sleep data (night wake, sleep duration, mid-
sleep and sleep efficiency) and assessed cross-sectionally for depression (BDI score).  
 
DNA methylation levels of BMAL1 in the brains were determined using bisulphite 
pyrosequencing and these were tested for any correlations between the CpG sites on 






3.1 Reagents and Supplies 
All the kits, reagents, chemicals and any other laboratory equipment used in this project 
can be found in the appendix. 
 
3.2 Study Population and Questionnaires 
The prefrontal cortex samples used in this project were obtained from the Manchester 
Brain Bank which were from The University of Manchester Longitudinal Study of 
Cognition in Normal Healthy Old Age cohort (Rabbitt et al., 2004).  
 
This study started in 1983 and 6375 participants were recruited from Greater 
Manchester and Newcastle upon Tyne for 10 years. Before the study started, written 
informed consent was gained from all participants and the self-report and questionnaire 
data was collected under the approval of The University of Manchester research ethics 
committee. The study consisted of five waves which were assessed between 1982 and 
2010 and in which Personal Details Questionnaire (PDQ) were performed. The first PDQ 
questionnaire was performed in recruitment until 1995; along with a depression survey. 
The second PDQ questionnaire was performed between 1984 and 1996 and the third 
PDQ was performed between 2001 and 2003. The fourth and fifth PDQ were completed 
in 2007 and 2010, respectively (Didikoglu et al., 2019). The fifth wave also included 
validated sleep questionnaires, including Pittsburgh Sleep Quality Index (PSQI).  
 
A total of 3477 participants attended a minimum of two test session whilst 212 people 
completed PDQs at all time points. The average age at the first visit was 65.19 ± 7.45 
years and a total of 69.9% of the cohort was female. This project investigated n=96 of 
these samples; 64 females & 32 males with females making up 66.7%. Vocabulary, fluid 
intelligence, processing speed and memory cognitive tests were collected longitudinally 
biennial in waves and these are included in the analysis. The methods of these cognitive 
assessments were previously described by Rabbitt et al., (2004).  
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The time at which the tests were completed was not noted so could not be accounted 
for during statistical analysis. Additionally, time of death and post mortem delay was 
also not noted or accounted for.  
 
Brain samples were acquired from donors through the Manchester Brain Bank. Ethical 
approval was granted from the Manchester Brain Bank Committee. All participants had 
provided written consent to donating their post-mortem samples to the brain bank for 
research purposes.  
 
COSHH forms and risk assessments were completed prior to the beginning of this study 
to ensure that all necessary precautions were taken to ensure safety and security, when 
in the laboratory.  
 
3.3 Brain Pathology Assessments 
The brain samples had been assessed and scored at the brain bank by experienced 
pathologists using the ‘ABC score’ which is recommended by National Institute on 
ageing – Alzheimer’s Association (Hyman et al., 2012). Only the Braak – neurofibrillary 
tangles stage (Braak & Braak, 1991) score was used in this analysis. Braak is the 
assessment of AD-related neurofibrillary pathology that allows the differentiation 
between initial, intermediate and late stages of AD. This is done by looking at the gradual 
deposition of hyperphosphorylated tau protein within selected neuronal types in 
specific nuclei or areas central to the disease process.  
 
3.4 DNA Extraction 
Fresh, frozen tissue was taken from superior frontal gyrus (Brodmann area 8) of the 
frontal cortex from 96 donors. These were extracted using Bioline Isolate II genomic DNA 
kit (Bioline, UK), following the manufacturers protocol. Throughout the cutting process, 
the samples were kept on dry ice to ensure no thawing of the tissues.  
 
Once DNA had been extracted, purity and concentration were both measured using 
Nanodrop 2000c spectrophotometer (Thermo Scientific, Wilmington, USA). Purity ratios 
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of A260/A280 were used to assess DNA purity and to ensure the DNA was free from 
protein contamination. The mean ratio of the absorbance at 260 and 280 nm (A260/280) 
of the 96 samples was 1.89 (StdDev .118). 
 
3.5 Bisulphite Conversion 
The DNA samples were diluted with water in separate Eppendorf tubes, in order to 
achieve an equal concentration of 500 ng/μL and working mix of 40 μl, following the 
guidelines from Qiagen EpiTect Fast Bisulphite Conversion Handbook Table (table 1). 
 
 












The samples turned from green 
to blue when DNA Protect 
Buffer was added, indicating sufficient mixing and correct pH for the bisulphite 
conversion reaction. The Eppendorf tubes were then incubated in the Eppendorf 
Mastercycler, using thermal conditions specified according to the Handbook (table 2). 
 














Low Concentration samples 
(1-500ng) 
Volume per reaction (μl) 
DNA 
 
Variable (Maximum 40 μl) 













Step Description  Time Temperature [°C]  
1 Denaturation  5 minutes  95  
2 Incubation  10 minutes  60  
3 Denaturation 5 minutes  95  
4 Incubation  10 minutes  60  




After the PCR finished, the rest of the protocol was followed according to the Qiagen 
Handbook. A total of 15 μl of DNA was eluted and stored at -20° C until used for analysis. 
 
3.6 Designing of BMAL1 primer 
 
The genomic browser (https://genome-euro.ucsc.edu/index.html), was used to search 
the gene BMAL1. The primers were designed using Pyromark Assay Design SW 2.0 
(Qiagen Pyromark Assay Design). The assay was shown with different sets of forward, 
reverse and sequencing primers with a score out of 100. The forward, reverse, 
sequencing primers and sequence to analyse are shown in table 3. 
 












































Sequence to Analyse 
 
AYGTAAAGAA YGTGAGAATA TTTGTAGTTT 
TYGGGGTGGA AATGTTTTTT AGAAATATTA 
AGTATTYGTT TTTTYGTTGA GATTTTGGTA 
AATTAGGGAT TTTAGGAAGG GTTTGGTATT 
TAAYGTTTTT AAAATTGGTT TTTTAGATG 
/\ 






Figure 2: A - Genomic Map of BMAL1. Squares represent gene exons. Transcription of gene occurs 
from left to right as shown by arrow. Schematic representation – not to scale. B- BMAL1 sequence 
to analyse. Highlighted with the forward, sequence and reverse primers and each CpG site location 
in the sequence.   
 
 
3.8 Polymerase chain reaction (PCR) 
To avoid foreign DNA contamination, the following was prepared in a PCR workstation. 
Master mix was prepared on ice using the reagents and volumes in table 4 and 18 μl 
added to a 96-well PCR plate. 2μl of DNA was then added but outside of the workstation 
to avoid risk of contamination and to create a total volume of 20 μl. The plate was 
covered with an adhesive seal to secure the contents and once secured, it was vortexed 
and then amplified using the Eppendorf Mastercycler thermal cycler with the steps 




Amount (1 reaction) 




















Table 5: DNA amplification PCR thermal cycling conditions 
Step Description Temperature (o C) Time Number of 
Cycles Per 
Step 





5 minutes 1 cycle 
 
2 
Denaturation 95 30 seconds  
50 cycles 
Annealing 56 30 seconds 
Extension 72 30 seconds 
3 Hold 4 Indefinite 1 cycle 
The PCR products were stored at -20 o C until samples were used for analysis.  
3.9 Agarose Gel Electrophoresis 
2% agarose gels were used in gel electrophoresis. To make these, 100 ml of 1 x TBE 
buffer (tris, boric acid and EDTA) is mixed with 2 g of agarose powder and heated in the 
microwave for 1-2 minutes, until completely clear; being mixed every 15-20 seconds to 
ensure the solution does not erupt. Once cool enough, 5 μl Midori Green Advance DNA 
Stain (NIPPON Genetics Europe) is added and mixed in the beaker. The gel was poured 
into a tray with combs already placed for the wells and waited to set for 20-30 minutes.  
The gel was placed into a Biorad tank with 1 x TBE buffer and a 50bp DNA hyperladder 
(Bioline), was added to the first well. The amplified samples were then prepared with 2 
μl loading dye per 6 μl of PCR DNA sample and added into the wells and the gel was 










electrophoresed at 90V for 30-60 minutes. Once finished, the gel images were viewed 
using the Odyssey® Fc imaging system (LI-COR Biotechnology, UK).  
 
3.10 Bisulphite Pyrosequencing 
DNA methylation analysis for BMAL1 was carried out using the bisulphite 
pyrosequencing method on the Pyromark Q24 System (Qiagen, Hilden, Germany) 
following the manufacturer’s protocol. The workstation was prepared, using 70% 
ethanol, denaturing solution, wash buffer and distilled water and placing them in the 
correct locations and the heat block (DB-2D, Dri-Block®, Techne) set to 85oC with the 
Q24 plate holder placed on top. A master mix was made containing Streptavidin 
Sepharose High Performance Beads (GE Healthcare Biosciences), Pyromark Binding 
Buffer and PCR-grade water to the ratio of 1:40:29 respectively. In a 24-well PCR plate, 
70 μL of this master mix was combined with 10 μL of PCR product in each well and 
covered with a film then placed on a TS-100 Thermo-shaker (Biosan) at 1400RPM for 10 
minutes. The sequencing primer was diluted to 0.3μM by adding 2.2 μL of primer stock 
to 712.8μL of Annealing Buffer and vortexed. 25 μL of this was then added to each well 
of a Pyromark Q24 Plate and then placed in the appropriate place on the work station.  
After the 10 minutes of shaking, the samples were placed on the workstation to be 
processed with the lid removed carefully and the vacuum turned on. To process the 
samples, the vacuum was placed into the samples for 15 seconds to ensure all the liquid 
had gone and was in the probes filter. The vacuum was then placed into the 70% ethanol 
for 5 seconds, denaturing buffer for 5 seconds and then the wash buffer for 10 seconds. 
Next, the vacuum was tilted vertically for a few seconds to allow any excess wash buffer 
to pass through, then was placed onto the Q24 plate containing the diluted primer with 
the vacuum switched off and shaken from side to side to dislodge the beads. The Q24 
plate was transferred onto the heat block (DB-2D, Dri-Block®, Techne) and incubated for 
2 minutes at ~85o C.  
 
The cartridge was cleaned using distilled water to ensure the channels were clear and 
not blocked from previous use. The cartridge was then loaded with enzyme mix, 
substrate mix and PyroMark deoxy nucleotide triphosphates (dNTPs) in proportions to 
pre run information for the specific run determined by the PyroMark Advanced 
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software. Both this cartridge and the Q24 plate were loaded into the machine and the 
run started.  
 
Once the run was completed, analysis of the methylation levels were determined using 
the PyroMark Q24 analysis feature.   
 
 Figure 3: Pyrogram showing the methylation % of CpG sites analysed on BMAL1. 
 
 
3.11 Pyrosequencing Assay Optimization & Troubleshooting  
The main issue that was experienced with the pyrosequencing method was the initial 
signal strength at 0 which would cause a negative number for the rest of the sample. To 
troubleshoot this, the volume of PCR product added into the sequencing reaction was 
increased from 10 μL to 15 μL, and the volume of water was reduced accordingly; 
ensuring the concentration of other reagents remained constant. This increased the 
signal strength and stopped any negative numbers; allowing all samples to be 
sequenced. This was the case with 29 of the samples and all are included in this analysis.  
 
For quality control purposes, five samples per each 24 samples sequenced, were chosen 
at random and sequenced twice. The mean was then taken for both results to get a final 
methylation result. Six CPG sites on the BMAL1 gene were successfully assessed for 
methylation levels. 
 
     CpG1      CpG2               CpG3                            CpG4  CpG5                                      CpG6 
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3.12 Cognitive Scores 
All the cognitive data used for the analysis in this study were obtained previously by 
Rabbitt et al., (2004). Longitudinal scores for fluid intelligence, processing speed, 
memory and vocabulary were used for analysis and each were taken biennially. 
 
For fluid intelligence, the tests were Alice Heim Tests (1970), also called AH4-1 and AH4-
2, and the Cattell and Cattell (1960) “Culture Fair” Test overall total correct score. AH4-
1 consists of logic, arithmetic and completion of number series and verbal comparisons. 
AH4-2 consists of non-verbal problems in which participants must select alternative 
solutions to the correct completions of logical series that are defined by either 
progressive mental rotation, addition and subtraction or other comparisons of line-
drawn shapes (Rabbitt et al., 2004) - both intelligence tests were 65 problems long and 
volunteers were encouraged to solve as many of the 65 problems as they could in 10 
minutes. The score was calculated with the total number of correct answers and the 
total number of items attempted.  
All four parts of the Cattell and Cattell (1960) “Culture Fair” non-verbal test of general 
fluid intelligence were included. This test incorporates 46 non-verbal problems with 
each part only lasting 2.5-4 minutes each. It involves a sequence of pictures with one 
missing and a specific question relating to the images. The participant must select which 
one is missing out of a possible 5 images. The score was the total correct score  
 
For the processing speed factor, the contributing measures were the Visual Search task 
and Letter Search Tests. The Visual Search Task consisted of capital letters printed on 
pages appearing in random orders, with the participants being given 8 minutes to detect 
all occurrences of the letters I and O. Scores were the numbers of targets detected and 
omitted, for example to measure both scanning rate and a direct measure of accuracy 
also. The Letter Search Test was the Savage (1984) Alphabet Coding Task that is a 
letter/letter coding task. The participants encoded random sequences of 15 different 
letters of the alphabet as quickly as possible, using a guide printed as a heading on each 
score sheet. This was run 4 consecutive times with each lasting 2 minutes during which 
the code remained constant. This was scored with the numbers of letters correctly 
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coded during each of these runs and also, the numbers of code letters correctly recalled 
after all runs had been completed. 
 
For the memory factor, there were 8 available measures: the 10-item free recall test, 
the coding/letter-letter substitution test, the propositions about people test, the 
memory circle test (total correct object and position), the 30-item free recall test, the 
verbal free recall test, cumulative free recall test and delayed recall test. All tests were 
designed specifically to test different aspects and areas of the brain and scores were 
recorded accordingly (Rabbitt et al., 2004). 
 
For vocabulary, the Raven (1965) Mill Hill A and Raven (1965) B vocabulary tests were 
used. A vocabulary test required a selection of the most exact synonym for 33 words 
from a possible 6 and B vocabulary test required generation of an exact definition of the 
meaning of each 33 words and there were no time limits. The score was calculated with 
the total number of correct answers and the total number of items attempted. In 
addition to these tests, The Wechsler Adult Intelligence Scale (WAIS) (Wechsler, 1986), 
was also used. WAIS produces scores on four separate subsets of adult intelligence. 
These are: the Perceptual Reasoning Index (PRI), the Verbal Comprehension Index (VCI), 
the Working Memory Index (WMI) and the Processing Speed Index (PSI). Scores are 
calculated based on each of these and then combined to create a Full-Scale IQ (FSIQ).  
 
Participants with severe auditory or visual handicaps were excluded from the 
longitudinal study. 
 
3.13 Cognition Used Model 
Cognitive g factors (vocabulary, fluid intelligence, processing speed and memory) 
derived from longitudinal biennial measures were included in the analysis. The methods 
of these cognitive assessments were previously described by Rabbitt et al., (2004); they 
included an intercept and slope per fluid, vocabulary, speed and memory which 
represent two different perspectives. Intercept is estimate of function at age 70 years 
from the longitudinal model while slope is the measure of change over time from model. 
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3.14 Sleep Data 
Sleep questions within the PDQ included “Generally, at what time do you go to bed at 
night?”, “Generally, at what time do you get up in the morning?”, “On average, how 
many hours sleep do you get every night?”, “How many times during the night do you 
wake up?” and “Do you have any difficulty in getting to sleep?”. Sleep efficiency (%) was 
calculated as “sleep duration x 100/(getting up time-going to bed time)” – sleep 
efficiency above 100% was accepted as 100%. Before analysis, data was cleaned from 
outliners for sleep times (Didikoglu et al., 2019). 
 
3.15 Depression Data 
The Beck Depression Inventory (BDI) (Beck et al., 1988) was used to measure depression 
and the scores for this were continuous. The self-score questionnaire included “I do not 
feel sad”, “I am not particularly discouraged about the future”, “I don’t cry any more 
than usual” and “I have lost interest in other people”. Each has three options to how 
much the participant agrees with the statement and they must choose one.  
 
 
3.16 Statistical Analysis 
All statistical analyses were performed using Stata Statistical Software (Release 14. 
College Station, TX: StataCorp LP). The significance threshold was accepted at p<0.05. 
Data obtained was tested for normal distribution using the Kolmogorov-Smirnov test. 
Data considered to be normally distributed is presented as Mean ± Standard Deviation 
(SD) and data not normally distributed is presented as Median ± Range unless otherwise 
stated. T tests were used for normally distributed data and Mann Whitney U tests for 
not normally distributed data to determine differences in methylation levels between 
the genders. Data was analysed using Pearson Correlation to determine association 
between pathology group (Braak score) and methylation amount per CpG sites, and one-
way analysis of variance (ANOVA) to determine differences between Alzheimer’s 
Groups. Pearson correlation was used to analyse methylation amounts and score of 
longitudinal cognition change; separately for men and women. For longitudinal sleep 
data analysis, linear mixed model was used to analyse methylation, adjusting for age 
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and sex. For cross-sectional depression data, linear regression was used to analyse 




4.1 BMAL1 Methylation Levels 
The mean methylation percentages for all samples per each CpG site are presented in a 
bar graph (figure 4) to indicate the methylation % per each site CpG site. The mean 
methylation percentages for all samples per each CpG site were: CpG1 (5.77 ± 6.93), 
CpG2 (4.80 ± 6.18), CpG3 (7.76 ± 6.34), CpG4 (7.15 ± 5.69), CpG5 (8.40 ± 6.48) and CpG6 
(3.48 ± 3.50). Methylation levels were not significantly different between males (n=32) 
and females (n=64) at any CpG site (p= > 0.05).  
 
4.2 BMAL1 Methylation and Neuropathology 
In association with the Braak & Braak, (1991) criteria, control, intermediate and AD were 
split into groups by the Brain Bank defined by their Braak score. For control purposes, 
the highest score was used. For example, a Braak score of IV-V, meant V was taken and 
used. 2 samples could not be classified into a classification due to Braak score being 
unavailable, so these were omitted from the analysis.  
 
A Pearson Correlation test was used to analyse Braak stage and methylation revealing 
that CpG site 2 positively correlated with Braak stage (r=0.26, p=0.01) but lost 
significance when accounting for multiple analysis. CpG sites 1, 3, 4, 5 and 6 did not 
significantly associate. Samples were grouped into AD (Braak stage V-VI) and Non-AD 
(Braak stage 0-IV). Mean methylation of each CpG between the groups are shown in 
Figure 4 with CpG site 2 again showing a significant difference (t ( 92)=-2.47, p=0.015) 
with higher methylation in the AD group. When samples were grouped into control, 
intermediate and AD by Braak stage, Control (Braak 0-II) (n=46), Intermediate (Braak III-
IV) (n=36), AD (Braak V-VI) (n=12), AD group have more CpG2 methylation then 
intermediate and control groups (F(2,91)=3.02, p=0.05). This suggestive significance is 




Figure 4: Methylation of CpG sites comparing Braak stage. Mean ± 95% CI is presented. n=94; 
Control (Braak 0-II) n=46, Intermediate (Braak III-IV) n=36, AD (Braak V-VI) n=12.  *= significant 




4.3 BMAL1 Methylation and Longitudinal Change in Cognition 
A Pearson Correlation test was used to analyse longitudinal cognition scores and BMAL1 
methylation. No significance was found between fluid intelligence, processing speed 
and memory cognitive tests, though for vocabulary CpG 1 (r=0.20, p=0.05) and CpG4 
(r=0.20, p= 0.05) showed positive correlations that did not remain significant when 
accounting for multiple analysis. Average methylation across all CpGs showed a non-
significant association (p=0.06) with vocabulary.  When testing intercept (age-adjusted 
cross-sectional data), CpG2 showed positive correlations with fluid intelligence (r=0.20 
p= 0.05) and vocabulary (r=0.22 p=0.03) that again did not remain significant when 






Table 6: A Pearson Correlation test to analyse cognitive measures and CpG methylation.  
Variable  CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 
Longitudinal Fluid intelligence 0.05  0.06  0.06  0.14  0.10  0.15  
Longitudinal Processing Speed 0.16 -0.01 -0.08 0.01 -0.04  0.05 
Longitudinal Memory 0.06 0.08 0.11 0.13 0.10 0.12 
Longitudinal Vocabulary 0.20* 0.13 0.12 0.20* 0.12 0.15 
Intercept Fluid intelligence 0.11 0.20* 0.06 0.05 0.05 0.04 
Intercept Processing Speed 0.10  0.08 0.01 -0.03 -0.03 0.03 
Intercept Memory 0.10 0.07 0.09 0.09 0.07 0.08 
Intercept Vocabulary 0.18  0.22* 0.11 0.09 0.05  0.07 
 




4.4 BMAL1 Methylation and Sleep  
 
Sleep characteristics of the samples used in this study are shown in table 10. A cross-
sectional analysis was performed using linear regression adjusted for age and sex to 
analyse methylation % per CpG and sleep data for the Pittsburgh Sleep Quality Index 
(PSQI). Data for PSQI was only available for 38 participants and there were no significant 
findings between any CpG island and PSQI total score (supplementary table 2). However, 
CpG4 showed a non-significant trend (F(3, 34)=1.92, p=0.06). 
 
Table 7: Sleep Characteristics of the samples used in this study. PDQ (Personal Detail 
Questionnaire), SD: standard deviation, h: hour, m: minute. %: percent/100. Mean ages at each 
wave were, respectively 1- 62.66 ± 5.32, 2- 66.24 ± 5.49, 3- 77.90 ± 5.4, 4- 83.03 ± 5.25, 5- 85.0 ± 
5.45 (mean ± SD). PDQ4 for night wake was not collected.    
 
 Night wake 
 
(number of times) 
 












  n       mean ± SD 
PDQ1 91 1.14 ± 1.08 93 7.13 ± 1.16 94 3.58 ± 0.65 93 86.23 ± 12.49 
PDQ2 70 1.24 ± 1.08 73 7.16 ± 1.18 73 3.6 ± 0.70 73 85.25 ± 12.37 
PDQ3 42 2.01 ± 1.06  42 6.95 ± 1.29  44 3.28 ± 0.68  42 80.66 ± 12.83 
PDQ4    70 6.64 ± 1.19  74 3.23 ± 0.74 69 77.38 ± 13.63 
PDQ5 42 2.31 ± 1.07  52 7.01 ± 1.43 51 3.14 ± 0.7 51 77.91 ± 14.1 
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A longitudinal analysis was performed using linear mixed model adjusted for age and 
sex to analyse sleep data and methylation percent per CpG site. Mixed-effects ML 
regression was used for n=95. No significance was found between sleep duration, 
midsleep and efficiency for any CpG sites (supplementary table 3). However, night wake 


















Figure 5: A positive correlation between number of night wakes and % of methylation of CpG 




Figure 6: A positive correlation between number of night wakes and % of methylation of CpG 




4.5 BMAL1 Methylation and Depression  
A cross-sectional analysis was performed using linear regression adjusted for age and 
sex to analyse methylation % per CpG and depression score using Beck Depression 
Inventory score (BDI). No significance was found between CpG site 2, 3, 5 or 6 and BDI 
score. However, CpG4 was positively associated with BDI score (F(3, 89)= 5.64, p = 0.02) 
and CpG1 showed a non-significant trend F(3, 89)= 4.91, p = 0.06). 
Table 8: Methylation % and BDI score using linear regression adjusted for age and sex.*= 
significant at 0.05 level. 
BDI Score*CpG site (n=93) F P Value 
BDI Score * CpG1 (3, 89)=4.91 0.06 
BDI Score * CpG2 (3, 89)=3.50 0.96 
BDI Score * CpG3 (3, 89)=3.52 0.82 
BDI Score * CpG4 (3, 89)=5.64 0.02* 
BDI Score * CpG5 (3, 89)=3.53 0.75 
BDI Score * CpG6 (3, 89)=4.55 0.09 
 
4.6 Overview & Summary of CpG sites 
 
Table 9: Overview of CpG site results. The arrows indicate a positive &/or negative correlation. F 
= females (n=64); M = males (n=32). Almost significant correlations are also shown. 
 
 
This study found that: CpG1 associates with BDI score to a nearly significant level, CpG2 
associates with Braak score, CpG3 associates with night wake, CpG4 associates with fluid 
intelligence in males, vocabulary in females and BDI score, CpG5 also associates with 
night wake and CpG6 associates with fluid intelligence in males.   
 CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 
Braak score       
Fluid intelligence    M  M 
Processing Speed       
Memory       
Vocabulary    F   
PSQI    0.06   
Night wake       
Sleep Duration       
Mid-sleep       
Efficiency        




5.1 General findings 
The study investigated the associations between methylation on 6 CpG sites on the 
BMAL1 gene, with Braak score, cognition scores of fluid intelligence, processing speed, 
memory and vocabulary in males and females, sleep data including night wakes, sleep 
duration, midsleep and efficiency and BDI (depression) score. The results found that 
CpG2 was associated with Braak score, CpG3 was associated with night wake, CpG4 was 
associated with female vocabulary, male fluid intelligence and BDI score, CpG5 was 
associated with night wake and CpG6 was associated with male fluid intelligence.  
 
5.2 Braak Score & Methylation 
It was found in this study that CpG2 was positively correlated with Braak score (p=0.01). 
Additionally, CpG2 was also nearly significant (p=0.05), when comparing the differences 
between the pathology groups and CpG sites. These results suggest that BMAL1 is 
regulated with Braak score to some extent and that levels of BMAL1 methylation is 
associated with higher levels of Aβ. 
 
The positive correlation between methylation with Braak stage suggests a reduced 
activity of BMAL1 with increased AD pathology, specifically tau and neurofibrillary 
tangles. Tau pathology has been shown to be the earliest observable AD-like change in 
human brain, with abnormal tau phosphorylation and aggregation beginning as early as 
young adulthood and extending to other connected regions even before Aβ is detected 
(Braak et al., 2011). Several animal studies find mechanistic links between tau pathology 
and circadian clock gene disruption. Koss et al., (2016) showed that transgenic mice with 
forebrain mutant human tau expression show increased wake and decreased NREM 
sleep, as well as more robust changes in EEG power than observed in transgenic mice 
with both tau and Aβ. A transgenic mouse model that develop progressive tau pathology 
leading to formation of neurofibrillary tangles, show a long free-running period 
indicating a disruption in the circadian rhythm. They further show disruption in the cyclic 
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expression of BMAL1 and other circadian clock genes in the hippocampus (Stevanovic 
et al., 2017).  
 
Additionally, the methylation rhythm of the BMAL1 promoter changes in the pre-frontal 
cortex of patients with AD. Lim et al., (2014) found that post-mortem human prefrontal 
cortex samples revealed attenuated methylation rhythms from samples with AD when 
compared with control. The rhythms of DNA methylation were then related with 
rhythms of RNA expression determined by RNA sequencing to support the evident of 
significant 24-hour rhythmicity of DNA methylation. These studies could explain why 
CpG2 was positively correlated with Braak score which could be due to the specific CpG 
islands tested on the BMAL1 gene. However, distinguishing the cause from effect in 
epigenetic epidemiology is difficult due to disorders such as AD manifesting in tissues 
that are inaccessible and are not capable of collecting for longitudinal study.  
 
Another study has shown that BMAL1 expression peaks at night (Cermakian et al., 2011) 
and along with PER1 & PER2, displayed significant 24-hour rhythmicity in the brains of 
AD patients. However, a desynchrony in oscillation was found between the cortex, Bed 
Nucleus of the Stria Terminalis (BNST) and pineal gland in AD patients (Cermakian et al., 
2011); possibly due to the degeneration of the SCN cells in AD brains. This suggests that 
BMAL1 methylation, as well as other CLOCK gene methylation, would have to be looked 
at in other parts of the brain and not just limited to the pre-frontal cortex. Due to the 
BNST and cingulate cortex being involved in decision-making, as well as the pineal gland 
being a major output of the SCN, the abnormal rhythms observed in these areas may 
contribute to cognitive and sleep-wake deficits in AD patients (Coogan et al., 2013).  
 
5.3 Cognition & Methylation 
AD is characterised by cognitive dysfunction. This includes thinking, reasoning and 
remembering. The tests used in this study were fluid intelligence, processing speed, 
memory and vocabulary and only longitudinal scores were used. It is widely reported 
that sleep deprivation is a major factor affecting cognitive performance. Multiple studies 
report this, with particular focus on tasks mediated by the prefrontal cortex function 
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(Harrison & Horne, 2000; Jones & Harrison, 2001). Additionally, it has been previously 
reported that memory and learning are regulated through the circadian timekeeper 
(Monk et al., 1997; Wright et al., 2002; Lyons et al., 2006). If memory and learning are 
regulated by the circadian clock and AD is characterised by disruption to the circadian 
rhythm, then it could be hypothesised and assumed that memory and learning would 
deteriorate as AD worsens and the circadian clock is further disrupted.  
 
In this study, a positive correlation was found for male fluid intelligence and CpG4 
methylation (p=0.04) and CpG6 methylation (p=0.04). Vocabulary and CpG4 methylation 
for females (p = 0.03) were also positively correlated. It is noted, within the central 
nervous system that clock timings were not restricted to the SCN, and ancillary 
oscillatory capacity has been detected in a variety of brain regions and cell types, 
including forebrain circuits that underlie complex cognitive processes (Snider et al., 
2016). Previous research in mice, suggest that essential signalling events in the 
hippocampus required for memory, depend on BMAL1 (Wardlaw et al., 2014). It was 
reported that mice who were completely arrhythmic in constant conditions, had 
impaired spatial learning and memory. This supports the theory that cognition 
performance is dependent on the circadian clock. Snider et al, (2016) also reported in 
mice, when BMAL1 was selectively deleted from excitatory forebrain neurons but the 
SCN clock remained the same, deficits in both acquisition and recall were observed. 
These studies suggest that both the clock timings and BMAL1, play a critical role in 
cognitive performance and for both learning, and memory retrieval.  
 
Only fluid intelligence and vocabulary were positively correlated to the CpG sites tested 
in this study. Due to testing for gender differences, this could be the reason why there 
are differences in correlations. It has been previously reported that men had relatively 
later rhythms of DNA methylation than women (Lim et al., 2014) and in particular, the 
expression of BMAL1, varied based on daily timings but was significantly earlier in 
women than in men (Lim et al., 2013). In addition to any gender differences, there are 
other aspects which could be very important. Burke et al., (2015) found that attention, 
mood and reaction time showed circadian variation when tested at different times 
throughout the day. This would suggest that other factors would have to be included, 
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for example, time at which the cognition tests were undertaken, and this could be 
adjusted for when completing the statistical analysis.  
 
5.4 Sleep Tests & Methylation 
Sleep disturbances and lack of sleep are extremely common within the general 
population; with sleep disturbances and disorders in the elderly affecting more than 
80% of people over 65 years old (Foley et al., 1995), but these numbers are even higher 
for people with AD (Van Someren, 2000). Severe lack of sleep contributes to increased 
risk of cardio-metabolic disorders like cardiovascular diseases and type 2 diabetes, as 
well as mental disorders (Porkka-Heiskanen et al., 2013). In this study, night wake had a 
positive correlation with CpG3 and CpG5 methylation, however, sleep duration, mid 
sleep and efficiency did not have a correlation to any of the CpG sites tested.  
 
Multiple regions in the brain are responsible for the regulation of sleep/wake states, 
however, the ventrolateral preoptic area (VLPO) in the anterior hypothalamus and the 
SCN are implemented in age related changes (Sherin et al., 1996). The VLPO contains 
galaninergic and GABAergic neurons which send inhibitory signals to arousal areas 
whilst asleep (Wennberg et al., 2017). Lesions to the VLPO have been associated with 
long-lasting insomnia in rats (Lu et al., 2000) which could also explain the mechanism in 
humans, and of which is observed in AD. 
 
Sleep deprivation on both the transcriptome and methylome has been studied and 
looked at in human samples and experimental animal models (Cirelli & Tononi, 2000; 
Benedict et al., 2014; Massart et al., 2014; Cedernaes et al., 2015). Cedernaes et al., 
found that a single night of wakefulness, or missing one nighs sleep, altered the 
epigenetic and transcriptional profile of core circadian clock genes (including BMAL1) in 
a number of key metabolic tissues; BMAL1 methylation in particular, decreased in 
skeletal muscle. When comparing against nightshift and dayshift workers, Bhatti et al., 
(2015) found a significant decrease in overall average methylation in the clock genes. 
Additionally, a CpG island near the transcription start site of BMAL1 was also 
hypomethylated, suggesting it be overexpressed amongst nightshift workers. An 
increase in BMAL1 expression has also been found amongst shift workers when 
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compared with night work, supporting this theory (Bracci et al., 2014). This could suggest 
why night wake was significant in this study. Work history, if known, would also have to 
be adjusted for when performing the statistical analysis as this could have a very 
prominent effect on BMAL1 methylation levels. 
 
AD patients tend to have disrupted sleep patterns and sleep disorders, as well as 
suffering from OSA (Wennberg et al., 2017) and SDB (Hermann & Bassetti, 2016) and an 
estimated 70-80% of people with dementia potentially suffer (Wennberg et al., 2017). 
SDB has been associated with several negative health problems, including 
cardiovascular disease (Young & Peppard, 2000) and diabetes (Punjabi et al., 2004) and 
the most common form is OSA. OSA is characterised by episodes of upper airway closure 
during sleep which results in intermittent hypoxia, impaired gas exchange and arousal 
from sleep (Shashri et al., 2015). OSA has also been found to be associated with poor 
executive functioning (Saloria et al., 2002; Sutton, 2008), a decline in verbal episodic 
memory (immediate recall, delayed recall, learning and recognition) and visuo-spatial 
episodic memory (immediate and delayed recall) (Wallace & Bucks, 2012). Ayalon et al., 
(2010) also found that performance for attention and recall was reduced with OSA and 
increasing age. Additionally, OSA has also been associated with MCI and dementia, with 
it being estimated in longitudinal studies that there is a 2-6 times greater risk of 
developing MCI or dementia (Yaffe et al., 2011; Chang et al., 2013). It has been 
suggested that OSA is associated with several brain changes, including loss of regional 
volume (Kumar et al., 2008), as well as white matter integrity in the cingulate cortex 
(Macey et al., 2008), hippocampus (Joo et al., 2013) and some cerebellar regions (Kim 
et al., 2013). As the majority of these are also symptoms of AD and OSA is also very 
common in AD, it is difficult to establish which is the cause and which is the 
consequence; OSA has associations with a decline in cognition which could be the 
decline that accompanies AD, or it could be the AD causing the OSA.  
 
In order to regulate the circadian clock, the SCN receives input from various time cues 
such as daylight exposure. The level of light received is a very important factor in 
synchronising the circadian system and AD patients could exhibit reduced circadian 
rhythm amplitude due to the SCN becoming less responsive to light as it exhibits reduced 
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neuronal activity (Swaab et al., 2002). The first process of the light signals being 
converted into neural signals is naturally affected in the ageing population due to 
reduced optical transmission at short wavelengths (Turner & Mainster, 2008; Brondsted 
et al., 2013) resulting in less light reaching the back of the eye. Light exposure can either 
expand or compress the circadian period, potentially leading to a change in timing or 
phase, however, the degree of change varies depending on the intensity, timing and 
duration of light exposure (Phan & Malkani, 2018). Older people, particularly those 
institutionalised with AD, are more likely to lead an indoor lifestyle; resulting in a 
decrease in bright light during the day which could lead to circadian disruptions. Studies 
found that the light conditions in nursing or care homes were not sufficient for both 
visual and the non-visual aspects of light (Riemersma et al., 2008; Sloane et al., 2008). 
Figueiro et al., (2015) found that lighting intervention significantly increased circadian 
entrainment in AD, in regard to phasor magnitude and sleep efficiency, whilst also 
decreasing symptoms of depression. This disruption in circadian rhythm can lead to 
sleep problems with symptoms including daytime sleepiness, napping during the day 
and wandering during the night (Nolan et al., 2003); all of which are common in AD 
(Bliwise, 2004). Furthermore, studies also found Aβ deposits in the retina of AD mice 
(Ning et al., 2008; Koronyo-Hamaoui et al., 2011) and also in vivo in humans (Koronyo 
et al., 2017), suggesting that Aβ accumulation also affects the retina. 
 
This suggestion also leads to the hypothesis that the sleep-wake cycle directly influences 
levels of Aβ in the brain due to sleep deprivation being shown to increase the 
concentration of soluble Aβ in mice; resulting in the accumulation of Aβ (Kang et al., 
2009). In human cerebrospinal fluid, Huang et al., (2012) found that Aβ concentrations 
were correlated to total sleep time, providing the link between sleep and Aβ 
accumulation. There are also other aspects of sleep that links Aβ accumulation. For 
example, sleep is often characterised into two general states measured by 
polysomnography: non-rapid eye movement (non-REM) sleep and rapid eye movement 
(REM) sleep. Non-REM consists of three stages, N1, N2 and N3 with slow wave sleep 
(SWS) being the deepest point of N3 (Wennberg et al., 2017). The main physiological 
difference between SWS and being awake is down to changes in neuronal activity and 
these neuronal firings release Aβ into the brain interstitial fluid, thus leading to an 
 42 
increase in concentration of Aβ in the interstitial fluid when awake (Cirrito et al., 2005). 
During SWS, the majority of the neurons are in the hyperpolarised silent state, which 
releases less Aβ than during other stages of sleep, or wakefulness (Ju et al., 2014). This 
means that if SWS is not reached during sleep, the cortical neurons will fire and 
depolarise, leading to an increase in the release of Aβ and thus, higher levels in the 
interstitial fluid. Kang et al., (2009) also found the levels of extracellular Aβ in mice was 
~25% higher during wakefulness compared with sleep, and persistently elevated Aβ 
levels in sleep deprivation conditions. These studies show the connection between sleep 
and Aβ accumulation, however it is difficult to establish whether the Aβ plaques seen in 
AD are the cause or consequence of sleep disturbances or if they exacerbate and 
accelerate the onset of AD pathology. If Aβ is accumulated due to lack of sleep, but AD 
is characterised by Aβ and lack of sleep, establishing the precursor remains difficult 
however, it is clear that they both influence each other to some extent. 
 
Poor sleep has also been linked to an increase in cognitive decline, which again is a 
hallmark of AD. Both short sleep duration (Kronholm et al., 2009; Xu et al., 2011; 
Stenberg et al., 2013) and long sleep duration (Schmutte et al., 2007; Kronholm et al., 
2009; Ramos et al., 2013) have been linked to poorer cognitive performance. Kronholm 
et al., (2009) found that both short and long sleep duration, as well as tiredness and 
fatigue were associated with a decrease in self-reported and objectively assessed 
cognitive functioning. Additionally, sleep duration has also been linked to poorer 
cognitive performance (Loerbroks et al., 2010; Ferrie et al., 2011) and a risk factor for 
dementia. Loerbroks et al., (2010) found a sleep duration of ≥9hours was associated 
with the impairment of verbal memory. Additionally, it was also found that increasing 
sleep duration from 7-8 hours to ≥9 hours was also associated with an increase in 
cognitive impairment. This again provides the link between AD pathology and sleep; 
however, the cause or consequence question still remains but it could be hypothesised 
that poor sleep helps contribute to AD pathology.  
 
The examples above are all factors of AD and sleep however for all it is hard to 
distinguish which is the cause and which is the consequence. As all are hallmarks of AD 
which lead to disruptions in sleep, it could be hypothesised that poor sleep is a result of 
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AD. However, there is significant evidence to support the hypothesis that poor sleep 
definitely contributes to AD pathology and potentially could lead to AD with a 
bidirectional link appearing between disturbed sleep and AD. 
 
 
5.5 Depression & Methylation 
Cognitive impairment is the hallmark of AD; however, depression is also common in a 
large number of AD patients with up to 50% of patients experiencing depression or 
clinically depressive symptoms (Starkstein et al., 2005). Additionally, between 80%-90% 
of depressed patients report insomnia, with insomnia also being a risk factor for 
developing depression (Reynolds & Kupfer, 1987). DNA methylation percentages were 
determined for each CpG site and tested for correlation against BDI score; CpG4 was 
positivity associated with BDI score (p=0.02) and CpG1 was nearly significantly 
associated (p=0.06). These results indicate that BMAL1 plays some role in depression.  
 
Disruptions in circadian rhythm have been previously associated with psychiatric 
illnesses such as depression (Sahar & Sassone-Corsi, 2012) and its different forms (Baird 
& Cauvin, 2000; Abarca et al., 2002); as well as Bipolar Disorder (Yang et al., 2008). The 
mechanism linking the two is likely represented by uncoupling of autonomous 
oscillators in the SCN or disruptions in the output from the SCN to other parts of the 
brain (Yang et al., 2008). Clock genes have been associated with depression and 
individuals with an abnormally-shifted or arrhythmic biological clock have been linked 
to a higher risk of developing depression (McClung, 2007). In animal models, 
Christiansen et al., (2016) found that BMAL1 in particular, along with PER2, was more 
susceptible to stress. Landgraf et al., (2016) also found that SCN-specific BMAL1-
knockdown mice exhibited depression-like behaviour. Polymorphisms in clock genes 
have also been investigated and reported to manifest in depressed patients (Partonen 
et al., 2007; Kovanen et al., 2013; Shi et al., 2016). These studies provide the link 
between the circadian cycle and depression; however, it is unclear if one or all are 
related. As BMAL1 is the main driver of the circadian cycle, it could be assumed that 
polymorphisms and degradation of this would in turn affect the other clock genes, 
potentially resulting in a higher risk of developing depression. 
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Additionally, there are other aspects that circadian timing controls, for example 
neurotransmitters. Studies have implicated the presence of a large number of 
neurotransmitters in the SCN (Rusak & Bina, 1990; Reghunandanan et al., 1991; 
Abrahamson & Moore, 2001). Dysregulated neurotransmission has been observed in AD 
(Selkoe, 2002; Martorana & Koch, 2014) and dopamine (DA) has been identified as a 
crucial neurotransmitter that is involved in long-term memory and motor activity. 
Martorana & Koch., (2014) found in AD-affected mice brains, that Aβ plaque-induced 
dopaminergic dysfunction was observed. The dopaminergic system has been studied as 
a key neurotransmitter system that is involved in cognition and emotion (Nardone et al., 
2014) because of the changes that it undergoes during the neuropathological ageing 
process. It has also been suggested that DA plays a key role in synaptic plasticity 
mechanisms (Hagena & Manahan-Vaughan, 2016). The disarrangement of synapses, 
impairment of neurotransmissions and cell losses promotes the presence of 
extracellular deposits of amyloid protein, plaques and intracellular fibrillary tangles 
which in turn, prompts the symptoms of predementia, like a decline in cognition (Pan et 
al., 2019). However, it is unclear whether the changes seen in AD patients is the cause, 
or effect of the disease, due to the changes to the dopaminergic pathways that occur 
naturally with age. Furthermore, changes in DA levels in the brain are suspected to 
influence mood in both humans and mice (Andretic & Hirsh, 2000; Nestler & Carlezon, 
2006; Roybal et al., 2007). As DA is an important neurotransmitter in depression and the 
DA system is disrupted with age and particularly with AD but is regulated with BMAL1 
and the circadian rhythm, then it could be hypothesised that depression is more a 
symptom of AD. However, it is unclear if depression comes before AD, or is rather a 
consequence of having AD.  
 
In addition to neurotransmitter dysfunction, another hallmark of AD is Aβ plaques and 
NFT, which have both also been linked to depression. It has been suggested that a 
lifetime history of depression is associated with Aβ deposition (Rapp et al., 2006; Wu et 
al., 2014; Chung et al., 2015). Rapp et al., (2006) found that AD patients with a lifetime 
history of depression corresponded to an increase in Aβ plaques and NFT when 
compared against AD patients without a history of depression. This suggests an 
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interaction between major depression and AD neuropathology. It has also been 
suggested that depressive symptoms in older age could be affected by Aβ pathology. 
Harrington et al., (2016) found that elevated Aβ levels were associated with an increased 
risk of developing clinically significant depression symptoms during follow-up in 
preclinical AD. Furthermore, it has also been found that people with MCI and depression 
were more than twice at the risk of developing AD than those without depression 
(Modrego & Ferrandez, 2004). There are clear links between depression, Aβ and AD and 
it could be hypothesised that depressive symptomatology could be an early symptom of 
underlying AD neuropathology. 
 
The prefrontal cortex has also been associated with depression (Treadway et al., 2015). 
The prefrontal cortex consists of two sub-regions, the ventromedial prefrontal cortex 
(vmPFC) and dorsolateral sectors (dlPFC) (Koenigs & Grafman, 2009), with each one 
being involved in different aspects of human physiology. The vmPFC is responsible for 
the regulation of affection, which includes the generation of negative emotions and the 
dIPFC is responsible for cognitive functions, including intention formation, attentional 
control and goal-directed action (Miller & Cohen, 2001) and both have been linked to 
depression. It has been found that in lesion models, loss of dIPFC can provoke 
depression, but loss of vmPFC can cause a decrease in the severity of depression 
(Ellenbogen et al., 2005; Sachdev & Sachdev, 2005). Additionally, it has been suggested 
that the mechanism in the prefrontal cortex that’s associated with depression is due to 
lack of activation of oxygenated haemoglobin (Pu et al., 2015). As only the prefrontal 
cortex was looked at during this study, the positive correlation that was found between 
BDI score and BMAL1 methylation could be due to the nature of the prefrontal cortex 
and it would be advised to investigate other brain regions to confirm the association. 
 
Furthermore, DNA methylation itself has been shown to play an important role in the 
pathogenesis of various stress-related psychiatric disorders, such as depression due to 
its reaction to external stress (Januar et al., 2015). Byrne et al., (2013) found in female 
monozygotic twins that a history of depression was associated with a decrease in global 
methylation levels when compared with control. Additionally, Numata et al., (2015) 
found lower methylation levels in patients with MDD when compared against control in 
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393 CpG sites using an epigenome-wise approach. This would suggest that DNA 
methylation levels tend to be lower in depressed patients. 
 
Despite the evidence mentioned which links alterations in circadian rhythms to 
behavioural disturbances and psychiatric diseases, it is challenging to determine 
whether circadian rhythm disturbances are the underlying cause of diseases or simply 




One limitation of this study is only BMAL1 methylation of one brain region (prefrontal 
cortex) was looked at. However, it is possible that DNA methylation varies across 
different brain regions. Further research should consider this possibility and investigate 
other regions of the brains and compare their DNA methylation variability on AD 
pathology. Additionally, the pre-frontal cortex samples used were from Manchester 
Brain Bank which, along with the data, were from The University of Manchester 
Longitudinal Study of Cognition in Normal Healthy Old Age cohort. As the samples were 
from here, the post-mortem delay was not known and could not be adjusted for when 
performing the statistical analysis.  
 
Another limitation to this study is sample size. Though 96 samples were investigated, all 
could not be used due to lack of relevant data. A larger sample size in which all the data 
could be used, would make for a more substantial statistical analysis. Furthermore, if 
the six CpG sites that were investigated were corrected for Bonferroni, as a conservative 
approach, significance would be lost due to limited samples with all the measures. 
 
An additional limitation is reporting error during PSQI/PDQ which are both self-reporting 
scales. Sleep data may be improved through use of wrist actigraphy studies. However 
due to this being a large cohort study, the PSQI/PDQ were deemed effective.  
 
A further limitation to this study would be the other factors that should be included. For 
example, time of death and time of tests undertaken. In the discussion, it was reviewed 
how these could have an effect on BMAL1 methylation and how it could change 
throughout the day. Due to this, these should be accounted for in the statistical analysis 
if possible and known throughout the longitudinal data analysis. 
 
However, the study also has several strengths. To my knowledge, this is the first study 
that has examined the association between BMAL1 methylation in post-mortem pre-




Additionally, this is the first study to use the data obtained from The University of 
Manchester Longitudinal Study of Cognition in Normal Healthy Old Age cohort and 
relate them to BMAL1 methylation and observe correlations with neuropathology, 
cognition decline, sleep data and depression scores.  
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7.0 Future Research 
 
This study has shown that BMAL1 methylation is linked to Braak score, cognitive decline, 
sleep waking and depression. However, the cause or consequence question still remains 
unanswered and it is still not known if BMAL1 methylation is the cause of these 
correlations or rather a consequence instead.  
 
Further research should consider longitudinal data if possible, for cognition tests, sleep 
and depression and relate to the different stages of AD. This would allow analyses to be 
conducted as AD progresses and relate to this. Additionally, further research needs to 
be conducted on gene regulation in cognitive decline and AD using human brain 
samples. This study should be repeated using another region of the brain, for example 
the hippocampus, to allow comparison to the prefrontal cortex and to assess if the levels 
are altered at all in different regions. Manipulating BMAL1 and studying effects in other 
brain regions will shed light on circadian clocks in brain regions that play a direct role in 
cognition function, sleep and mood regulation.  
 
Furthermore, this study has highlighted the importance of sleep on AD pathology and 
further work may be able to consider a longitudinal study of care home sleeping patterns 
against people in their own homes by looking at ways to help improve sleep. Also, a 
longitudinal study that focuses on sleep and AD but with light therapies would help 
support the data found in this study. 
 
Other clock genes should also be looked at and this study should be repeated but with 
PER1, PER2, & PER3 and CRY1 & CRY2 with the use of the same data. This will help form 
a mechanistic view of the circadian cycle and the role it plays in AD neuropathology, 









The use of human brain samples from the prefrontal cortex in this study allowed us to 
develop a mechanistic view of how the DNA methylation of BMAL1 methylation, AD 
neuropathology, cognition, sleep and depression may all be linked together (figure 11).  
 
This study found that BMAL1 methylation was positively associated with Braak score, 
longitudinal fluid intelligence score for males, longitudinal vocabulary for females, night 
wakes and depression (BDI score). However, surprisingly, no significance or associations 
were found between BMAL1 and processing speed and memory tests, sleep duration, 
mid-sleep and sleep efficiency. These results suggest that BMAL1 methylation does play 
a role in sleep and AD neuropathology but to what extent needs further research. As the 
circadian cycle is linked to sleep and sleep highly linked to the circadian cycle, it could 
only be hypothesised that all play a role in AD neuropathology.  
 
Further studies should look at other important CLOCK genes and relate their 
methylation to sleep and AD. This will help create a more robust view of the circadian 
cycle and give insight into how much influence sleep has on CLOCK gene methylation 









Figure 7: The proposed bidirectional relationship between BMAL1 methylation, AD and 
sleep. Potential positive-feedback mechanisms exist between BMAL1 methylation, Aβ 
accumulation, sleep quality, AD and cognitive decline. Aβ=Beta-amyloid; AD=Alzheimer’s Disease; 
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10.0 Appendix: Supplementary Material 
 
 
Table 1: Chemical, reagents and kits used: 
 
96 well plate  Starline  
Q24 sequence plate  Quigen  
0.2ml PCR tubes  Starline  
Pipette tips 10ul,20ul,200ul,1000ul  
 
PCR plate cover slips  
 
Nuclease free water  
 
PCR grade water  
 
Isolate 2 genomic DNA extraction kit  Bio line  
EpiTec fast Bisulphite kit  Quigen  
Pyromark q24 regents  Quigen  
Agarose powder  
 




DNA ladder 100bp  Bioline  
MyTaqHS  Bioline  
70% ethanol  
 
Denaturing buffer  
 
Washing buffer  
 
BMAL1 forward primer  Invergion  
BMAL1 reverse primer  Invergion 
BMAL1 sequence primer  Invergion  
Biorad RT PCR Machine Biorad 
Eppendorf master cycler  
Pyromark sequencer Quigen 
Biorad power pack and tank Biorad 
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Table 2: PSQI Score and CpG site using linear regression adjusted for age and sex. No CpG sites 




















Table 3: Sleep data and CpG site usng linear mixed model adjusted for age and sex. *= 

















CpG1 0.92 0.97 0.47 0.84 
CpG2 1.0 0.28 0.89 0.86 
CpG3 0.33 0.71 0.90 0.03* 
CpG4 0.17 0.94 0.28 0.76 
CpG5 0.21 0.99 0.69 0.01** 
CpG6 0.35 0.49 0.40 0.82 
 
PSQI * CpG site (n=38) 
 
F P Value 
PSQI * CpG1 
 
(3, 34)=0.64 0.96 
PSQI * CpG2 
 
(3, 34)=0.64 0.94 
PSQI * CpG3 
 
(3, 34)=0.64 0.93 
PSQI * CpG4 
 
(3, 34)=1.92 0.06 
PSQI * CpG5 
 
(3, 34)=0.70 0.68 
PSQI * CpG6 
 
(3, 34)=1.79 0.08 
